434P Myeloprotection with trilaciclib prior to first-line chemotherapy in extensive-stage small cell lung cancer: An integrated analysis of clinical trials
Conclusions: Baseline immune and transcriptomic features are linked with durable clinical benefit in ES-SCLC pts treated with chemo-IT and may guide personalized ITbased treatment.
Authors
- Laura Alder (ORCID: https://orcid.org/0000-0003-2228-4094)
- M Dietrich
- Ralph V. Boccia
- J. Weiss
Institutions
- University of North Carolina at Chapel Hill (US)
- Center for Cancer and Blood Disorders (US)
- Cancer Care Centers of Brevard (US)
- Duke Institute for Health Innovation (US)
- Duke Medical Center (US)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-03-17
- DOI
- https://doi.org/10.1016/j.esmoop.2026.106748
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00